[1] |
Chew C, Lennon R. Basement membrane defects in genetic kidney diseases[J]. Front Pediatr, 2018, 6: 11.
doi: 10.3389/fped.2018.00011
pmid: 29435440
|
[2] |
Borza DB. Glomerular basement membrane heparan sulfate in health and disease: a regulator of local complement activation[J]. Matrix Biol, 2017, 57-58: 299-310.
|
[3] |
Naylor RW, Morais MRPT, Lennon R. Complexities of the glomerular basement membrane[J]. Nat Rev Nephrol, 2021, 17(2): 112-127.
doi: 10.1038/s41581-020-0329-y
|
[4] |
Aumailley M. Laminins and interaction partners in the architecture of the basement membrane at the dermal-epidermal junction[J]. Exp Dermatol, 2021, 30(1): 17-24.
doi: 10.1111/exd.14239
pmid: 33205478
|
[5] |
Togawa H, Nakanishi K, Mukaiyama H, et al. First Japanese case of Pierson syndrome with mutations in LAMB2[J]. Pediatr Int, 2013, 55(2): 229-231.
doi: 10.1111/j.1442-200X.2012.03629.x
|
[6] |
Funk SD, Lin MH, Miner JH. Alport syndrome and Pierson syndrome: diseases of the glomerular basement membrane[J]. Matrix Biol, 2018, 71-72: 250-261.
|
[7] |
Cosgrove D, Liu S. Collagen IV diseases: a focus on the glomerular basement membrane in Alport syndrome[J]. Matrix Biol, 2017, 57-58: 45-54.
|
[8] |
Cummings CF, Pedchenko V, Brown KL, et al. Extra-cellular chloride signals collagen IV network assembly during basement membrane formation[J]. J Cell Biol, 2016, 213(4): 479-494.
doi: 10.1083/jcb.201510065
|
[9] |
Quinlan C, Rheault MN. Genetic basis of type IV collagen disorders of the kidney[J]. Clin J Am Soc Nephrol, 2021, 16(7): 1101-1109.
doi: 10.2215/CJN.19171220
|
[10] |
Kashtan CE, Ding J, Garosi G, et al. Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group[J]. Kidney Int, 2018, 93(5): 1045-1051.
doi: S0085-2538(18)30085-1
pmid: 29551517
|
[11] |
Zhang JL, Richetti S, Ramezani T, et al. Vertebrate extracellular matrix protein hemicentin-1 interacts physically and genetically with basement membrane protein nidogen-2[J]. Matrix Biol, 2022, 112: 132-154.
doi: 10.1016/j.matbio.2022.08.009
|
[12] |
Wnuk M, Anderegg MA, Graber WA, et al. Neuropilin1 regulates glomerular function and basement membrane composition through pericytes in the mouse kidney[J]. Kidney Int, 2017, 91(4): 868-879.
doi: S0085-2538(16)30609-3
pmid: 27988210
|
[13] |
Darbro BW, Mahajan VB, Gakhar L, et al. Mutations in extracellular matrix genes NID1 and LAMC1 cause autosomal dominant Dandy-Walker malformation and occipital cephaloceles[J]. Hum Mutat, 2013, 34(8): 1075-1079.
doi: 10.1002/humu.22351
|
[14] |
Lin PY, Hung JH, Hsu CK, et al. A novel pathogenic HSPG2 mutation in Schwartz-Jampel syndrome[J]. Front Neurol, 2021, 12: 632336.
doi: 10.3389/fneur.2021.632336
|
[15] |
Xia P, Xie F, Zhou ZJ, et al. Novel LG1 mutations in agrin causing congenital myasthenia syndrome[J]. Intern Med, 2022, 61(6): 887-890.
doi: 10.2169/internalmedicine.7774-21
|
[16] |
Chen Z, Migeon T, Verpont MC, et al. HANAC syndrome Col4a1 mutation causes neonate glomerular hyperpermeability and adult glomerulocystic kidney disease[J]. J Am Soc Nephrol, 2016, 27(4): 1042-1054.
doi: 10.1681/ASN.2014121217
|
[17] |
Savige J, Harraka P. Pathogenic LAMA5 variants and kidney disease[J]. Kidney360, 2021, 2(12): 1876-1879.
doi: 10.34067/KID.0007312021
|
[18] |
Nozu K, Nakanishi K, Abe Y, et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome[J]. Clin Exp Nephrol, 2019, 23(2): 158-168.
doi: 10.1007/s10157-018-1629-4
pmid: 30128941
|
[19] |
Shan LD, Peng J, Xiao H, et al. Clinical features and COL4A1 genotype of a toddler with hereditary angiopathy with nephropathy, aneurysms and muscle cramps syndrome[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2019, 21(8): 754-760.
|
[20] |
Kulali F, Calkavur S, Basaran C, et al. A new mutation associated with Pierson syndrome[J]. Arch Argent Pediatr, 2020, 118(3): e288-e291.
|
[21] |
Kamiyoshi N, Nozu K, Fu XJ, et al. Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome[J]. Clin J Am Soc Nephrol, 2016, 11(8): 1441-1449.
doi: 10.2215/CJN.01000116
|
[22] |
Savige J, Lipska-Zietkiewicz BS, Watson E, et al. Guidelines for genetic testing and management of Alport syndrome[J]. Clin J Am Soc Nephrol, 2022, 17(1): 143-154.
doi: 10.2215/CJN.04230321
|
[23] |
Kashtan CE. Alport syndrome: achieving early diagnosis and treatment[J]. Am J Kidney Dis, 2021, 77(2): 272-279.
doi: 10.1053/j.ajkd.2020.03.026
pmid: 32712016
|
[24] |
Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020[J]. Pediatr Nephrol, 2021, 36(3): 711-719.
doi: 10.1007/s00467-020-04819-6
pmid: 33159213
|
[25] |
Warady BA, Agarwal R, Bangalore S, et al. Alport syndrome classification and management[J]. Kidney Med, 2020, 2(5): 639-649.
doi: 10.1016/j.xkme.2020.05.014
|
[26] |
Torra R, Furlano M. New therapeutic options for Alport syndrome[J]. Nephrol Dial Transplant, 2019, 34(8): 1272-1279.
doi: 10.1093/ndt/gfz131
|
[27] |
Yamamura T, Horinouchi T, Adachi T, et al. Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5[J]. Nat Commun, 2020, 11(1): 2777.
doi: 10.1038/s41467-020-16605-x
|
[28] |
Lin MH, Miller JB, Kikkawa Y, et al. Laminin-521 Protein therapy for glomerular basement membrane and podocyte abnormalities in a model of pierson syndrome[J]. J Am Soc Nephrol, 2018, 29(5): 1426-1436.
doi: 10.1681/ASN.2017060690
|